U.S. Dermatological Drugs Market To Reach $14.48 Billion By 2030

U.S. Dermatological Drugs Market Growth & Trends

The U.S. dermatological drugs market size is anticipated to reach USD 14.48 billion by 2030, expanding at a CAGR of 9.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is driven by the availability of novel treatments designed for chronic skin diseases and the increasing prevalence of skin problems such as acne, psoriasis, and others. Increasing awareness regarding the significance of skin health in overall well-being also contributes to the growth.

Moreover, significant investments in research and development lead to new medications, and the availability of over-the-counter products makes treatments more accessible, contributing to overall growth. In recent years, multiple pharmaceutical and consumer healthcare companies have received U.S. FDA approvals for innovation-based products developed to treat severe skin conditions and enhance patient outcomes.

The emergence of new drug delivery systems and key market participants turning to collaboration-based research efforts in dermatology have also played vital roles in the market's growth. The large number of individuals seeking affordable treatments, the availability of over-the-counter products across retail pharmacies, and retailer service expansions with novel offerings such as fast delivery and online distribution are projected to add lucrative growth opportunities for this market over the forecast period.

 Request a free sample copy or view report summary: U.S. Dermatological Drugs Market Report

U.S. Dermatological Drugs Market Report Highlights

• Psoriasis dominated the therapy segment with more than 35.0% share in 2024, owing to many individuals seeking effective treatment for psoriasis and the focus of market participants on the delivery of novel therapies

• Dermatological drugs for acne are expected to grow at a significant CAGR in the U.S. over the forecast period

• The prescription-based dermatological drugs held the largest market share, 77.5%, in 2024. The over-the-counter segment is anticipated to witness significant growth over the forecast period

• Topical administration dominated the U.S. dermatological drugs market, with a revenue share of 60.0% in 2024, owing to patients' treatment experiences, patient-friendly delivery systems, and ease of use. The parenteral administration segment is expected to witness the fastest CAGR of 10.7% over the forecast period

• Increasing investments in research and development, approvals received for numerous novel therapies and products, and convenience offered by retail pharmacies are contributing to the growth of the U.S. dermatological drugs market.

U.S. Dermatological Drugs Market Segmentation

Grand View Research has segmented the U.S. dermatological drugs market on the basis of therapy, type, route of administration, drug class, and distribution channel:

U.S. Dermatological Drugs Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Acne

• Psoriasis

• Rosacea

• Alopecia

• Others

U.S. Dermatological Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

• Prescription

• Over-the-Counter (OTC)

U.S. Dermatological Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Topical Administration

• Oral Administration

• Parenteral Administration

U.S. Dermatological Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

• Retinoids

• Antibiotics

• Antifungals

• Calcineurin Inhibitors

• Others

U.S. Dermatological Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Others

List of Key Players in the U.S. Dermatological Drugs Market

• AbbVie Inc.

• Pfizer Inc.

• GSK plc.

• LEO Pharma A/S

• Sun Pharmaceutical Industries Ltd.

• GALDERMA

• Amgen Inc.

• Johnson & Johnson Services Inc.

• Novartis AG

• Eli Lilly and Company

• Almirall, S.A

• Bausch Health Companies Inc.